FDA approves Remicade biosimilar

FDA approved Inflectra infliximab-dyyb (CT- P13) from Celltrion Inc. (KOSDAQ:068270), a biosimilar of Remicade infliximab from the Janssen Biotech Inc. unit of Johnson & Johnson

Read the full 252 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE